Yoshiko Umeyama

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto et al. · European Journal of Cancer · 2011 · 123 citations

Urology, Renal Function, Genitourinary Cancer +7

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada et al. · Liver Cancer · 2021 · 98 citations · Full text

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Kenji Tamura, Hirofumi Mukai, Yoichi Naito et al. · Cancer Science · 2016 · 89 citations · Full text

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda et al. · International Journal of Clinical Oncology · 2018 · 70 citations · Full text

Breast Oncology, Medicine, Pharmacology +9

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).

Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada et al. · Journal of Clinical Oncology · 2019 · 62 citations

Immunology, Pathology, Immunotherapeutics +21